治疗前治疗组和对照组血清IL-18无明显差别（P>0.05）,较正常健

Before treatment treatment group and control group serum IL-18 was no significant difference (P> 0.05), significantly higher than normal healthy group. The above-described levels of inflammatory factors in patients after 12 months of active treatment, two groups of therapeutically significantly lower than before treatment (P <0.05), but still significantly higher than the control group. And blood levels of IL-18 treatment group was significantly lower than the control group, the difference was statistically significant (P <0.05).

There was no significant difference in serum IL-18 (P.0.05) in the pre-treatment group and the control group, which was significantly higher than in the normal healthy group. After 12 months of active treatment, the above-mentioned inflammatory factors were significantly lower on average than before treatment in both groups of patients given treatment, but were still significantly higher than in the normal control group. The blood IL-18 level in the treatment group was significantly lower than that of the control group, and the difference was statistically significant (P 0.05).

Before treatment, there was no significant difference in serum IL-18 between the treatment group and the control group (P > 0.05), which was significantly higher than that of the normal healthy group. After 12 months of active treatment, the levels of inflammatory factors in the two groups were significantly lower than those before treatment (P < 0.05), but still significantly higher than those in the normal control group. The level of IL-18 in the treatment group was significantly lower than that in the control group (P < 0.05).<br>